GlassScriptPhysician profile
Alexis Gonzalez Rivera
NPI 1609214618
$15,731.98
in general payments reported to CMS, 2019-2025
20 companies · $750 in 2025
The $750 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,131 · 2020: $197 · 2021: $462 · 2022: $2,819 · 2023: $9,760 · 2024: $613 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,005 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,100 · Food and Beverage: $2,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,005.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,100.00 |
| Food and Beverage | $2,017.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,812.60 | 2019-2025 | |
| Genzyme Corporation | $1,814.71 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $497.67 | 2020-2024 | Zeposia, Eliquis |
| Janssen Pharmaceuticals, INC | $287.12 | 2019-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $143.27 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $143.05 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $140.61 | 2019 | |
| Eisai INC. | $125.00 | 2019 | |
| Olympus Latin America, INC. | $124.96 | 2024 | Evis Exera III Colonovideoscope |
| Organon LLC | $112.01 | 2022-2024 | Renflexis, Hadlima |
| Janssen Scientific Affairs, LLC | $100.00 | 2019 | |
| Intercept Pharmaceuticals, INC. | $90.08 | 2020-2025 | Ocaliva |
| Pbg Puerto Rico LLC | $76.92 | 2021-2023 | |
| Biogen, INC. | $76.14 | 2021-2025 | Avonex, Vumerity, Tysabri |
| Janssen Biotech, INC. | $67.00 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer Pharmaceuticals LLC | $36.88 | 2019 | |
| Exact Sciences Corporation | $25.00 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $24.20 | 2021 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $18.33 | 2025 | Omvoh |
| Sunovion Pharmaceuticals INC. | $16.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Gonzalez Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.